<code id='939D030EEE'></code><style id='939D030EEE'></style>
    • <acronym id='939D030EEE'></acronym>
      <center id='939D030EEE'><center id='939D030EEE'><tfoot id='939D030EEE'></tfoot></center><abbr id='939D030EEE'><dir id='939D030EEE'><tfoot id='939D030EEE'></tfoot><noframes id='939D030EEE'>

    • <optgroup id='939D030EEE'><strike id='939D030EEE'><sup id='939D030EEE'></sup></strike><code id='939D030EEE'></code></optgroup>
        1. <b id='939D030EEE'><label id='939D030EEE'><select id='939D030EEE'><dt id='939D030EEE'><span id='939D030EEE'></span></dt></select></label></b><u id='939D030EEE'></u>
          <i id='939D030EEE'><strike id='939D030EEE'><tt id='939D030EEE'><pre id='939D030EEE'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          hotspot

          author:Wikipedia    - browse:9848
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia